<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T11:22:06Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4495878" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4495878</identifier>
        <datestamp>2015-07-17</datestamp>
        <setSpec>lwwopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Circ Cardiovasc Interv</journal-id>
              <journal-id journal-id-type="iso-abbrev">Circ Cardiovasc Interv</journal-id>
              <journal-id journal-id-type="publisher-id">HCV</journal-id>
              <journal-title-group>
                <journal-title>Circulation. Cardiovascular Interventions</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1941-7640</issn>
              <issn pub-type="epub">1941-7632</issn>
              <publisher>
                <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4495878</article-id>
              <article-id pub-id-type="pmcid">PMC4495878</article-id>
              <article-id pub-id-type="pmc-uid">4495878</article-id>
              <article-id pub-id-type="pmid">26047993</article-id>
              <article-id pub-id-type="art-access-id">00007</article-id>
              <article-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.114.002230</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>24</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                  <subj-group>
                    <subject>Coronary Interventions</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Comparison of Zotarolimus- and Everolimus-Eluting Coronary
Stents</article-title>
                <subtitle>Final 5-Year Report of the RESOLUTE All-Comers Trial</subtitle>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Iqbal</surname>
                    <given-names>Javaid</given-names>
                  </name>
                  <degrees>MRCP, PhD</degrees>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Serruys</surname>
                    <given-names>Patrick W.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Silber</surname>
                    <given-names>Sigmund</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kelbaek</surname>
                    <given-names>Henning</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Richardt</surname>
                    <given-names>Gert</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morel</surname>
                    <given-names>Marie-Angele</given-names>
                  </name>
                  <degrees>BSc</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Negoita</surname>
                    <given-names>Manuela</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Buszman</surname>
                    <given-names>Pawel E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Windecker</surname>
                    <given-names>Stephan</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <aff>From the Department of Interventional Cardiology, Erasmus Medical Centre,
Rotterdam, The Netherlands (J.I., P.W.S.); Department of Cardiovascular Science,
University of Sheffield, UK (J.I.); International Centre for Circulatory Health,
Imperial College London, London, UK (P.W.S.); Department of Cardiology, Heart
Centre at the Isar, Munich, Germany (S.S.); Righshospitalet, The Heart Center,
Copenhagen, Denmark (H.K.); Herzzentrum der Segeberger Kliniken, Bad Segeberg,
Germany (G.R.); Cardialysis BV, Rotterdam, The Netherlands (M.-A.M.); Medtronic,
Santa Rosa, CA (M.N.); Department of Cardiology, Medical University of Silesia,
Katowice, Poland (P.E.B.); and Department of Cardiology, Bern University
Hospital, Bern, Switzerland (S.W.).</aff>
              </contrib-group>
              <author-notes>
                <corresp id="c1">Correspondence to Patrick W. Serruys, MD, PhD, FESC, PO Box 2125,
3000 CC Rotterdam, The Netherlands. E-mail <email xlink:href="patrick.w.j.c.serruys@gmail.com">patrick.w.j.c.serruys@gmail.com</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>16</day>
                <month>6</month>
                <year>2015</year>
              </pub-date>
              <volume>8</volume>
              <issue>6</issue>
              <fpage>1</fpage>
              <lpage>8</lpage>
              <permissions>
                <copyright-statement>© 2015 The Authors.</copyright-statement>
                <copyright-year>2015</copyright-year>
                <license license-type="open-access">
                  <license-p><italic>Circulation: Cardiovascular Interventions</italic> is published on
behalf of the American Heart Association, Inc., by Wolters Kluwer. This is
an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/3.0/">Creative
Commons Attribution Non-Commercial-NoDervis</ext-link> License, which
permits use, distribution, and reproduction in any medium, provided that the
original work is properly cited, the use is noncommercial, and no
modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri xlink:type="simple" xlink:href="hcv-8-1.pdf"/>
              <abstract abstract-type="toc">
                <p>Supplemental Digital Content is available in the text.</p>
              </abstract>
              <abstract>
                <sec>
                  <title>Background—</title>
                  <p>Newer-generation drug-eluting stents that release zotarolimus or everolimus
have been shown to be superior to the first-generation drug-eluting stents.
However, data comparing long-term safety and efficacy of zotarolimus- (ZES)
and everolimus-eluting stents (EES) are limited. RESOLUTE all-comers
(Randomized Comparison of a Zotarolimus-Eluting Stent With an
Everolimus-Eluting Stent for Percutaneous Coronary Intervention) trial
compared these 2 stents and has shown that ZES was noninferior to EES at
12-month for the primary end point of target lesion failure. We report the
secondary clinical outcomes at the final 5-year follow-up of this trial.</p>
                </sec>
                <sec>
                  <title>Methods and Results—</title>
                  <p>RESOLUTE all-comer clinical study is a prospective, multicentre, randomized,
2-arm, open-label, noninferiority trial with minimal exclusion criteria.
Patients (n=2292) were randomly assigned to treatment with either ZES
(n=1140) or EES (n=1152). Patient-oriented composite end point (combination
of all-cause mortality, myocardial infarction, and any revascularizations),
device-oriented composite end point (combination of cardiac death, target
vessel myocardial infarction, and clinically indicated target lesion
revascularization), and major adverse cardiac events (combination of
all-cause death, all myocardial infarction, emergent coronary bypass
surgery, or clinically indicated target lesion revascularization) were
analyzed at 5-year follow-up. The 2 groups were well-matched at baseline.
Five-year follow-up data were available for 98% patients. There were no
differences in patient-oriented composite end point (ZES 35.3% versus EES
32.0%, <italic>P</italic>=0.11), device-oriented composite end point (ZES
17.0% versus EES 16.2%, <italic>P</italic>=0.61), major adverse cardiac
events (ZES 21.9% versus EES 21.6%, <italic>P</italic>=0.88), and
definite/probable stent thrombosis (ZES 2.8% versus EES 1.8%,
<italic>P</italic>=0.12).</p>
                </sec>
                <sec>
                  <title>Conclusions—</title>
                  <p>At 5-year follow-up, ZES and EES had similar efficacy and safety in a
population of patients who had minimal exclusion criteria.</p>
                </sec>
                <sec>
                  <title>Clinical Trial Registration—</title>
                  <p>URL: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier:
NCT00617084.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>drug-eluting stent</kwd>
                <kwd>everolimus</kwd>
                <kwd>percutaneous coronary interventions</kwd>
                <kwd>zotarolimus</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text position="float">
              <sec>
                <title>WHAT IS KNOWN</title>
                <list list-type="bullet">
                  <list-item>
                    <p>Newer-generation drug-eluting stents are superior to first-generation
drug-eluting stents.</p>
                  </list-item>
                  <list-item>
                    <p>Data comparing long-term safety and efficacy of the second-generation
zotarolimus- and everolimuseluting stents are limited.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>WHAT THE STUDY ADDS</title>
                <list list-type="bullet">
                  <list-item>
                    <p>RESOLUTE all-comer prospective, multicentre, randomized, 2-arm,
open-label, noninferiority trial randomized 2292 patients to treatment
with either zotarolimus- or everolimus-eluting stents and followed them
for 5 years.</p>
                  </list-item>
                  <list-item>
                    <p>At 5 years, there were no differences in patient-oriented composite end
point, device-oriented composite end point, major adverse cardiovascular
events, and definite/probable stent thrombosis between zotarolimus- or
everolimus-eluting stents–treated patients.</p>
                  </list-item>
                </list>
              </sec>
            </boxed-text>
            <p>Percutaneous coronary intervention has revolutionized the treatment of patients with flow
limiting coronary artery disease. Balloon angioplasty without stenting had limited
success because of a high incidence of acute vessel closure caused by dissection or
elastic recoil, late vascular remodeling, and neointimal proliferation.<sup><xref rid="R1" ref-type="bibr">1</xref>–<xref rid="R3" ref-type="bibr">3</xref></sup> The introduction of bare metal stents improved procedural success
and acute outcomes<sup><xref rid="R1" ref-type="bibr">1</xref></sup>; however, the
clinical outcomes remained affected by high risk of in-stent restenosis.<sup><xref rid="R4" ref-type="bibr">4</xref>–<xref rid="R6" ref-type="bibr">6</xref></sup> The drug-eluting stents (DES) substantially reduced neointimal
proliferation,<sup><xref rid="R5" ref-type="bibr">5</xref>–<xref rid="R7" ref-type="bibr">7</xref></sup> but first-generation DES eluting
sirolimus or paclitaxel from a durable polymer raised safety concerns about late and
very late stent thrombosis possibly because of delayed endothelialization by the
antiproliferative drugs and chronic inflammation or delayed hypersensitivity reaction
caused by the polymers in these DES.<sup><xref rid="R8" ref-type="bibr">8</xref>–<xref rid="R11" ref-type="bibr">11</xref></sup> The
second-generation DES have newer antiproliferative drugs (including zotarolimus and
everolimus) and biocompatible or biodegradable polymers along with improved stent design
and thinner struts.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> These newer
stents have shown promising results and improved clinical outcomes compared with
first-generation DES<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup>; however, the long-term data on direct comparison
between the newer-generation DES is scarce.</p>
            <p>The RESOLUTE all-comers (Randomized Comparison of a Zotarolimus-Eluting Stent With an
Everolimus-Eluting Stent for Percutaneous Coronary Intervention) trial aimed to compare
the Resolute zotarolimus-eluting stent (ZES; Medtronic CardioVascular Ltd) and Xience-V
everolimus-eluting stent (EES; Abbott Vascular Ltd).<sup><xref rid="R13" ref-type="bibr">13</xref></sup> It has been shown that ZES was noninferior to the EES with
respect to the primary end point of target lesion failure at 12 months, which occurred
in 8.2% and 8.3% of patients, respectively (<italic>P</italic>&lt;0.001 for
noninferiority). There were no significant between-group differences in the rate of
death from cardiac causes, any myocardial infarction, repeat revascularization, or stent
thrombosis at 12 months.We report the clinical outcomes at the final 5-year follow-up of
this trial.</p>
            <sec sec-type="methods">
              <title>Methods</title>
              <p>The study complies with the Declaration of Helsinki. Study protocol was approved by
the relevant ethics committees and informed consent was obtained from all
participants (or their guardians).</p>
              <sec>
                <title>Study Design and Population</title>
                <p>The study design of the RESOLUTE all-comers trial has previously been
described<sup><xref rid="R13" ref-type="bibr">13</xref></sup> and is
outlined in Figure <xref ref-type="fig" rid="F1">1</xref>. Briefly, the RESOLUTE
all-comers trial is a multicentre prospective double-arm randomized controlled
noninferiority trial. From April 30, 2008, to October 28, 2008, we recruited
2292 adult patients with chronic, stable coronary artery disease or acute
coronary syndromes, including myocardial infarction with or without
ST-segment–elevation. The trial was powered for noninferiority testing of
the primary end point at 12 months on an intention-to-treat basis; the details
of power calculation have been described previously.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> Patients were randomly assigned to undergo
percutaneous coronary intervention with either ZES or EES. Patients were
eligible if they had at least one coronary lesion with percentage diameter
stenosis &gt;50% in a vessel with a reference diameter of 2.25 to 4.0 mm.
There were minimal exclusion criteria and no restrictions on total number of
treated lesions, treated vessels, lesion length, or number of stents
implanted.</p>
                <fig id="F1" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Flow diagram of RESOLUTE all-comers trial. RESOLUTE indicates Randomized
Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting
Stent for Percutaneous Coronary Intervention.</p>
                  </caption>
                  <graphic xlink:href="hcv-8-1-g001"/>
                </fig>
              </sec>
              <sec sec-type="methods">
                <title>Study Procedure</title>
                <p>Procedures were performed according to standard techniques with the aim to treat
all coronary lesions in one session; however, staged procedures within 6 weeks
were permitted. Mixture of different DES types was prohibited unless the
operator was unable to insert the study stent. Procedural anticoagulation was
achieved with unfractionated heparin at a dose of 5000 IU or 70 to 100 IU per
kilogram of body weight to maintain an activated clotting time of &gt;250
seconds; the use of glycoprotein IIb/IIIa inhibitors was at the
operators’ discretion. All patients received at least 75 mg of
acetylsalicylic acid before the procedure. A loading dose of 300 to 600 mg of
clopidogrel was administered if the patient had received no clopidogrel during
the previous 7 days. All patients were discharged with a prescription of at
least 75 mg of acetylsalicylic acid indefinitely and 75 mg of clopidogrel for a
minimum of 6 months after the index procedure.</p>
              </sec>
              <sec>
                <title>Follow-Up and Clinical End Points</title>
                <p>Patients were followed-up by telephone call or hospital visit at 1, 6, and 12
months and yearly thereafter until 5 years. The primary end point of the trial
was target lesion failure (TLF) defined as the composite of cardiac death,
myocardial infarction (not clearly attributable to a nontarget vessel), and
target lesion revascularization (clinically indicated) at 12 months.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> The current article reports
the secondary clinical outcomes of this trial at final 5-year follow-up. These
predefined end points include device-oriented composite end point or TLF
(combination of cardiac death, myocardial infarction not clearly attributable to
a nontarget vessel, and clinically indicated target lesion revascularization),
patient-oriented composite end point (combination of all-cause mortality,
myocardial infarction, and any revascularizations), target vessel failure
(combination of cardiac death, myocardial infarction not clearly attributable to
a nontarget vessel, and clinically indicated target vessel revascularization)
and major adverse cardiac events (combination of all-cause death, all myocardial
infarction, emergent coronary bypass surgery, or clinically indicated target
lesion revascularization). We have also presented all the individual end points,
as defined previously,<sup><xref rid="R13" ref-type="bibr">13</xref></sup> and
stent thrombosis as defined by the Academic Research Consortium.<sup><xref rid="R15" ref-type="bibr">15</xref></sup></p>
              </sec>
              <sec>
                <title>Statistical Analysis</title>
                <p>Categorical variables are presented as counts and percentages and compared using
Chi-square or Fisher exact test. Continuous variables are presented as
means±standard deviation and compared using the Student’s unpaired
<italic>t</italic> test or 1-way analysis of variance, as appropriate.
Survival curves were constructed using Kaplan–Meier estimates and
compared using log-rank test. A 2-tailed <italic>P</italic> value of
&lt;0.05 was considered to indicate statistical significance. Statistical
analyses were performed using SAS version 9.2 (SAS Institute, Inc, Cary).</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <p>A total of 2292 patients were enrolled and randomly assigned to treatment with ZES
(n=1140) or EES (n=1152). The 2 groups were well-matched for the baseline
demographical, clinical, and angiographic characteristics, except for difference in
number of stents used, total length of stents used, and the maximum balloon pressure
(Table <xref ref-type="table" rid="T1">1</xref>), as previously reported.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> The mean age was 64±11
years, with 77% males and 23% diabetics in both groups. There were ≈34%
patients in both study arms who underwent revascularization for acute myocardial
infarction. The mean SYNTAX score was also similar in both groups (ZES
14.8±9.3 versus EES 14.6±9.2, <italic>P</italic>=0.63).</p>
              <table-wrap id="T1" position="float">
                <label>Table 1.</label>
                <caption>
                  <p>Comparison of Baseline Characteristics Between the Groups Treated With
Zotarolimus- and Everolimus-Eluting Stents</p>
                </caption>
                <graphic xlink:href="hcv-8-1-g002"/>
              </table-wrap>
              <p>Follow-up data at 5 years were available for 98% patients. There was no difference in
usage of dual antiplatelet therapy between the 2 groups at 30 day (ZES 93.9% versus
EES 94.3%, <italic>P</italic>=0.72), 1 year (ZES 84.2% versus 83.3%,
<italic>P</italic>=0.61), 2 year (ZES 17.8% versus 18.2%,
<italic>P</italic>=0.82), and 5 year (ZES 11.0% versus EES 10.9%,
<italic>P</italic>=0.94).</p>
              <p>At 5-year follow-up, there were no differences in the incidence of patient-oriented
(ZES 35.3% versus EES 32.0%, <italic>P</italic>=0.11) or device-oriented (ZES 17.0%
versus EES 16.2%, <italic>P</italic>=0.61) end points between the 2 groups (Figure
<xref ref-type="fig" rid="F2">2</xref>). Furthermore, we noted no differences
between the 2 stent groups for major adverse cardiac events (ZES 21.9% versus EES
21.6%, <italic>P</italic>=0.88) and target vessel failure (ZES 20.0% versus EES
19.1%, <italic>P</italic>=0.60) at the final follow-up (Figure <xref ref-type="fig" rid="F2">2</xref>). The 2 groups also had no difference in other clinical end
points, including death, cardiac death, myocardial infarction, revascularization,
and stent thrombosis (Table <xref ref-type="table" rid="T2">2</xref>). The detailed
incidence of stent thrombosis in the 2 groups during 5-year follow-up period is
provided in Table in the Data Supplement.</p>
              <table-wrap id="T2" position="float">
                <label>Table 2.</label>
                <caption>
                  <p>All Clinical End Points at 5-Year Follow-Up</p>
                </caption>
                <graphic xlink:href="hcv-8-1-g003"/>
              </table-wrap>
              <fig id="F2" position="float">
                <label>Figure 2.</label>
                <caption>
                  <p>Kaplan–Meier curves comparing zotarolimus- and everolimus-eluting
stents for clinical end points. Zotarolimus- and everlomius-eluting stents
had similar patient-oriented composite end point (PoCE; combination of
all-cause mortality, myocardial infarction, and any revascularization;
<bold>A</bold>), device-oriented composite end point (DoCE; combination
of cardiac death, myocardial infarction not clearly attributable to a
nontarget vessel, and clinically indicated target lesion revascularization;
<bold>B</bold>), target vessel failure (TVF; combination of cardiac
death, myocardial infarction not clearly attributable to a nontarget vessel,
and clinically indicated target vessel revascularization; <bold>C</bold>),
and major adverse cardiac events (MACE; combination of all-cause death, all
myocardial infarction, emergent coronary bypass surgery, or clinically
indicated target lesion revascularization; <bold>D</bold>). Error bars
indicate a point-wise 2-sided 95% confidence interval (1.96 SD). Standard
error based on the Greenwood Formula.</p>
                </caption>
                <graphic xlink:href="hcv-8-1-g004"/>
              </fig>
              <p>Stratified analysis of the primary end point (device-oriented composite end
point/TLF) at 5 years across different patient subgroups (including diabetics and
acute coronary syndromes) and anatomic complexity of coronary artery disease
revealed no difference in outcomes between ZES- and EES-treated patients (Figure
<xref ref-type="fig" rid="F3">3</xref>).</p>
              <fig id="F3" position="float">
                <label>Figure 3.</label>
                <caption>
                  <p>Forest plot showing prespecified subgroups analysis comparing zotarolimus-
and everolimus-eluting stents for target lesion failure at 5-year follow-up.
Zotarolimus- and everolimus-eluting stents had similar device-oriented
composite end point (DoCE) or target lesion failure (TLF), including
combination of cardiac death, myocardial infarction (MI) not clearly
attributable to a nontarget vessel, and clinically indicated target lesion
revascularization. Error bars indicate a point-wise 2-sided 95% confidence
interval (1.96 SD). Standard error based on the Greenwood Formula. EES
indicates everolimus-eluting stents; and ZES, zotarolimus-eluting
stents.</p>
                </caption>
                <graphic xlink:href="hcv-8-1-g005"/>
              </fig>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>The RESOLUTE all-comers trial directly compared the performance of 2 newer-generation
stents in an all-comers population over a long follow-up period. The main finding of
the present study is that at 5-year follow-up, ZES and EES were similar in clinical
efficacy and safety with no difference in either patient-oriented and
device-oriented end points or stent thrombosis.</p>
              <p>The DES are the main stay in treating patients with flow-limiting coronary
lesions.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> First-generation DES showed a substantial
improvement reduction in restenosis and need for repeat revascularization compared
with bare metal stents.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> However, these first-generation
devices failed in adding a major gain in terms of long-term mortality<sup><xref rid="R18" ref-type="bibr">18</xref></sup> and a major concern remained on
long-term safety, in particular, related to late stent thrombosis.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R19" ref-type="bibr">19</xref>–<xref rid="R24" ref-type="bibr">24</xref></sup> The second-generation DES, with
novel stent design/material, improved polymer biocompatibility, and novel
antiproliferative drugs were developed to improve acute performance and long-term
outcomes.<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup></p>
              <p>ZES and EES have previously been shown to be equivalent in terms of procedural
success, angiographic late lumen loss, and short-/midterm clinical
outcomes.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> Our data confirms that they remain comparable over a long
follow-up period of 5 years. These results are consistent with reports from other
trials and registries.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> The Real-World Endeavor Resolute
Versus Xience V Drug-Eluting Stent Study in Twente (TWENTE) trial randomly assigned
patients to ZES (n=697) or EES (n=694) and found no difference in patient-oriented
composite end point (ZES 16.4% versus EES 17.1%, <italic>P</italic>=0.75) and target
vessel failure (ZES 10.8% versus EES 11.6, <italic>P</italic>=0.65) at 2-year
follow-up.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> It has also
been shown that there is no difference in outcomes between the 2 stents when used
for patients with complex coronary disease,<sup><xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R30" ref-type="bibr">30</xref></sup> long lesions
requiring overlapping stents,<sup><xref rid="R31" ref-type="bibr">31</xref></sup>
unprotected left main stem,<sup><xref rid="R32" ref-type="bibr">32</xref></sup>
small diameter (&lt;2.7 mm) vessels,<sup><xref rid="R33" ref-type="bibr">33</xref></sup> and bifurcation lesions.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> Our findings from stratified analyses corroborate
these studies.</p>
              <p>The incidence of stent thrombosis in ZES- or EES-treated patients in this study was
similar and comparable to other studies. In the LEADERS trial, the incidence of
definite/probable stent thrombosis at 5 year for second-generation biolimus eluting
stent was 3.6%. In the TWENTE trial, 95% patients were asked to discontinue dual
antiplatelet therapy after 12 months. Two-year rates of definite or probable stent
thrombosis were similar (ZES 1.2% versus EES 1.4%,
<italic>P</italic>=0.63).<sup><xref rid="R27" ref-type="bibr">27</xref></sup></p>
              <p>ZES (cobalt-chromium platform) has been reported to be equivalent to the newer
platinum-chromium (Pt-Cr)– based EES (Promus Element, Boston Scientific
Ltd),<sup><xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup> whereas Pt-Cr–based (Promus Element) and
cobalt-chromium–based (Xience-V) EES are also comparable in
outcomes.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> HOST-ASSURE
trial randomized 3755 all-comer patients undergoing percutaneous coronary
intervention to PtCr-EES or ZES. At 1-year, the primary end point of TLF occurred in
2.9% and 2.9% of the population in the PtCr-EES and ZES groups, respectively
(superiority <italic>P</italic>=0.98, noninferiority <italic>P</italic>=0.025).
There were no significant differences in the individual components of TLF, as well
as the patient-oriented clinical outcome.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Another recently reported all-comer trial (n=1811 patients)
comparing cobalt-chromium–based ZES (n=906) against Promus Element (Pt-Cr
EES, n=905) has shown no difference in the primary end point of target vessel
failure or its individual components at 12-month follow-up. There was also no
difference in stent thrombosis (ZES 0.3% versus Promus Element 0.7%,
<italic>P</italic>=0.34).<sup><xref rid="R36" ref-type="bibr">36</xref></sup>
There was also no difference in the outcomes for patients presenting with
ST-elevation myocardial infarction.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p>
              <sec>
                <title>Limitations</title>
                <p>This study’s powered primary end point was target lesion failure at 1
year, and the clinical outcome at the final 5-year follow-up is a secondary end
point. However, it was a prespecified secondary end point, with all events
adjudicated by an independent Clinical Events Committee.</p>
              </sec>
              <sec sec-type="conclusions">
                <title>Conclusions</title>
                <p>ZES and EES offered similar patient- and device-related end points at 5-year
follow-up. Both ZES and EES are the most widely used DES at the moment, and our
results indeed confirm that these stents have equally good outcomes during a
long-term follow-up.</p>
              </sec>
            </sec>
            <sec>
              <title>Acknowledgments</title>
              <p>We express our gratitude to all study centres and participants in this trial, whose
work made this study possible.</p>
            </sec>
            <sec>
              <title>Sources of Funding</title>
              <p>This study was funded by Medtronic Vascular, Santa Rosa, CA. The funder had no
influence on analysing and interpretation of data.</p>
            </sec>
            <sec>
              <title>Disclosures</title>
              <p>Dr Silber has received research grants to the institution from Biotronik and St Jude.
Dr Richardt has received consultancy fee from Abbott Vascular. Dr Negoita is a full
time employee of Medtronic. The other authors report no conflicts.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <fig id="s1" position="anchor">
                <media xlink:href="hcv-8-1-s001.pdf"/>
              </fig>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="supplementary-material" id="fn01">
                <p>The Data Supplement is available at <ext-link ext-link-type="uri" xlink:href="http://circinterventions.ahajournals.org/lookup/suppl/doi:10.1161/CIRCINTERVENTIONS.114.002230/-/DC1">http://circinterventions.ahajournals.org/lookup/suppl/doi:10.1161/CIRCINTERVENTIONS.114.002230/-/DC1</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Feyter</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>de Jaegere</surname>
                      <given-names>PP</given-names>
                    </name>
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW.</given-names>
                    </name>
                  </person-group>
                  <article-title>Incidence, predictors, and management of acute coronary occlusion
after coronary angioplasty.</article-title>
                  <source>Am Heart J</source>
                  <year>1994</year>
                  <volume>127</volume>
                  <fpage>643</fpage>
                  <lpage>651</lpage>
                  <pub-id pub-id-type="pmid">8122614</pub-id>
                </element-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>de Jaegere</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kiemeneij</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Macaya</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Rutsch</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Heyndrickx</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Emanuelsson</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Marco</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Legrand</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Materne</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>A comparison of balloon-expandable-stent implantation with
balloon angioplasty in patients with coronary artery disease. Benestent
Study Group.</article-title>
                  <source>N Engl J Med</source>
                  <year>1994</year>
                  <volume>331</volume>
                  <fpage>489</fpage>
                  <lpage>495</lpage>
                  <comment>doi: 10.1056/NEJM199408253310801</comment>
                  <pub-id pub-id-type="pmid">8041413</pub-id>
                </element-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fischman</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Leon</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Baim</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Schatz</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Savage</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Penn</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Detre</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Veltri</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Ricci</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Nobuyoshi</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>A randomized comparison of coronary-stent placement and balloon
angioplasty in the treatment of coronary artery disease. Stent Restenosis
Study Investigators.</article-title>
                  <source>N Engl J Med</source>
                  <year>1994</year>
                  <volume>331</volume>
                  <fpage>496</fpage>
                  <lpage>501</lpage>
                  <comment>doi: 10.1056/NEJM199408253310802</comment>
                  <pub-id pub-id-type="pmid">8041414</pub-id>
                </element-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Strauss</surname>
                      <given-names>BH</given-names>
                    </name>
                    <name>
                      <surname>Beatt</surname>
                      <given-names>KJ</given-names>
                    </name>
                    <name>
                      <surname>Bertrand</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Puel</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Rickards</surname>
                      <given-names>AF</given-names>
                    </name>
                    <name>
                      <surname>Meier</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Goy</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Vogt</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kappenberger</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Angiographic follow-up after placement of a self-expanding
coronary-artery stent.</article-title>
                  <source>N Engl J Med</source>
                  <year>1991</year>
                  <volume>324</volume>
                  <fpage>13</fpage>
                  <lpage>17</lpage>
                  <comment>doi: 10.1056/NEJM199101033240103</comment>
                  <pub-id pub-id-type="pmid">1984159</pub-id>
                </element-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morice</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Sousa</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Fajadet</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ban Hayashi</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Perin</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Colombo</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Schuler</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Barragan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Guagliumi</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Molnàr</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Falotico</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <collab>RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx
Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo
Native Coronary Artery Lesions</collab>
                  <article-title>A randomized comparison of a sirolimus-eluting stent with a
standard stent for coronary revascularization.</article-title>
                  <source>N Engl J Med</source>
                  <year>2002</year>
                  <volume>346</volume>
                  <fpage>1773</fpage>
                  <lpage>1780</lpage>
                  <comment>doi: 10.1056/NEJMoa012843</comment>
                  <pub-id pub-id-type="pmid">12050336</pub-id>
                </element-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stone</surname>
                      <given-names>GW</given-names>
                    </name>
                    <name>
                      <surname>Ellis</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Cox</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Hermiller</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>O’Shaughnessy</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Turco</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Caputo</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bergin</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Greenberg</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Popma</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Russell</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <collab>TAXUS-IV Investigators</collab>
                  <article-title>A polymer-based, paclitaxel-eluting stent in patients with
coronary artery disease.</article-title>
                  <source>N Engl J Med</source>
                  <year>2004</year>
                  <volume>350</volume>
                  <fpage>221</fpage>
                  <lpage>231</lpage>
                  <comment>doi: 10.1056/NEJMoa032441</comment>
                  <pub-id pub-id-type="pmid">14724301</pub-id>
                </element-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moses</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Leon</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Popma</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Fitzgerald</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Holmes</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>O’Shaughnessy</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Caputo</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Kereiakes</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>DO</given-names>
                    </name>
                    <name>
                      <surname>Teirstein</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Jaeger</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Kuntz</surname>
                      <given-names>RE</given-names>
                    </name>
                  </person-group>
                  <collab>SIRIUS Investigators</collab>
                  <article-title>Sirolimus-eluting stents versus standard stents in patients with
stenosis in a native coronary artery.</article-title>
                  <source>N Engl J Med</source>
                  <year>2003</year>
                  <volume>349</volume>
                  <fpage>1315</fpage>
                  <lpage>1323</lpage>
                  <comment>doi: 10.1056/NEJMoa035071</comment>
                  <pub-id pub-id-type="pmid">14523139</pub-id>
                </element-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McFadden</surname>
                      <given-names>EP</given-names>
                    </name>
                    <name>
                      <surname>Stabile</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Regar</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Cheneau</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Ong</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Kinnaird</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Suddath</surname>
                      <given-names>WO</given-names>
                    </name>
                    <name>
                      <surname>Weissman</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Torguson</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kent</surname>
                      <given-names>KM</given-names>
                    </name>
                    <name>
                      <surname>Pichard</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Satler</surname>
                      <given-names>LF</given-names>
                    </name>
                    <name>
                      <surname>Waksman</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW.</given-names>
                    </name>
                  </person-group>
                  <article-title>Late thrombosis in drug-eluting coronary stents after
discontinuation of antiplatelet therapy.</article-title>
                  <source>Lancet</source>
                  <year>2004</year>
                  <volume>364</volume>
                  <fpage>1519</fpage>
                  <lpage>1521</lpage>
                  <comment>doi: 10.1016/S0140-6736(04)17275-9</comment>
                  <pub-id pub-id-type="pmid">15500897</pub-id>
                </element-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lagerqvist</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Carlsson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Fröbert</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Lindbäck</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Scherstén</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Stenestrand</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>James</surname>
                      <given-names>SK</given-names>
                    </name>
                  </person-group>
                  <collab>Swedish Coronary Angiography and Angioplasty Registry Study
Group</collab>
                  <article-title>Stent thrombosis in Sweden: a report from the Swedish Coronary
Angiography and Angioplasty Registry.</article-title>
                  <source>Circ Cardiovasc Interv</source>
                  <year>2009</year>
                  <volume>2</volume>
                  <fpage>401</fpage>
                  <lpage>408</lpage>
                  <comment>doi: 10.1161/CIRCINTERVENTIONS.108.844985</comment>
                  <pub-id pub-id-type="pmid">20031749</pub-id>
                </element-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joner</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Finn</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Farb</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mont</surname>
                      <given-names>EK</given-names>
                    </name>
                    <name>
                      <surname>Kolodgie</surname>
                      <given-names>FD</given-names>
                    </name>
                    <name>
                      <surname>Ladich</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kutys</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Skorija</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Gold</surname>
                      <given-names>HK</given-names>
                    </name>
                    <name>
                      <surname>Virmani</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pathology of drug-eluting stents in humans: delayed healing and
late thrombotic risk.</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2006</year>
                  <volume>48</volume>
                  <fpage>193</fpage>
                  <lpage>202</lpage>
                  <comment>doi: 10.1016/j.jacc.2006.03.042</comment>
                  <pub-id pub-id-type="pmid">16814667</pub-id>
                </element-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joner</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Nakazawa</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Finn</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Quee</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Coleman</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Acampado</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Skorija</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Cheng</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Gold</surname>
                      <given-names>HK</given-names>
                    </name>
                    <name>
                      <surname>Kolodgie</surname>
                      <given-names>FD</given-names>
                    </name>
                    <name>
                      <surname>Virmani</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Endothelial cell recovery between comparator polymer-based
drug-eluting stents.</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2008</year>
                  <volume>52</volume>
                  <fpage>333</fpage>
                  <lpage>342</lpage>
                  <comment>doi: 10.1016/j.jacc.2008.04.030</comment>
                  <pub-id pub-id-type="pmid">18652940</pub-id>
                </element-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Iqbal</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gunn</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW.</given-names>
                    </name>
                  </person-group>
                  <article-title>Coronary stents: historical development, current status and
future directions.</article-title>
                  <source>Br Med Bull</source>
                  <year>2013</year>
                  <volume>106</volume>
                  <fpage>193</fpage>
                  <lpage>211</lpage>
                  <comment>doi: 10.1093/bmb/ldt009</comment>
                  <pub-id pub-id-type="pmid">23532779</pub-id>
                </element-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Silber</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Garg</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>van Geuns</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Richardt</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Buszman</surname>
                      <given-names>PE</given-names>
                    </name>
                    <name>
                      <surname>Kelbaek</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>van Boven</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Hofma</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Linke</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Klauss</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Wijns</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Macaya</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Garot</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>DiMario</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Manoharan</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Kornowski</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Ischinger</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Bartorelli</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ronden</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Bressers</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gobbens</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Negoita</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>van Leeuwen</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Windecker</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparison of zotarolimus-eluting and everolimus-eluting coronary
stents.</article-title>
                  <source>N Engl J Med</source>
                  <year>2010</year>
                  <volume>363</volume>
                  <fpage>136</fpage>
                  <lpage>146</lpage>
                  <comment>doi: 10.1056/NEJMoa1004130</comment>
                  <pub-id pub-id-type="pmid">20554978</pub-id>
                </element-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stone</surname>
                      <given-names>GW</given-names>
                    </name>
                    <name>
                      <surname>Rizvi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Newman</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Mastali</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Caputo</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Doostzadeh</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Cao</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Simonton</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Sudhir</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lansky</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Cutlip</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>Kereiakes</surname>
                      <given-names>DJ</given-names>
                    </name>
                  </person-group>
                  <collab>SPIRIT IV Investigators</collab>
                  <article-title>Everolimus-eluting versus paclitaxel-eluting stents in coronary
artery disease.</article-title>
                  <source>N Engl J Med</source>
                  <year>2010</year>
                  <volume>362</volume>
                  <fpage>1663</fpage>
                  <lpage>1674</lpage>
                  <comment>doi: 10.1056/NEJMoa0910496</comment>
                  <pub-id pub-id-type="pmid">20445180</pub-id>
                </element-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cutlip</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>Windecker</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mehran</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Boam</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>van Es</surname>
                      <given-names>GA</given-names>
                    </name>
                    <name>
                      <surname>Steg</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Morel</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Mauri</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Vranckx</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>McFadden</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Lansky</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hamon</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Krucoff</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW</given-names>
                    </name>
                  </person-group>
                  <collab>Academic Research Consortium</collab>
                  <article-title>Clinical end points in coronary stent trials: a case for
standardized definitions.</article-title>
                  <source>Circulation</source>
                  <year>2007</year>
                  <volume>115</volume>
                  <fpage>2344</fpage>
                  <lpage>2351</lpage>
                  <comment>doi: 10.1161/CIRCULATIONAHA.106.685313</comment>
                  <pub-id pub-id-type="pmid">17470709</pub-id>
                </element-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wijns</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Kolh</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Danchin</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Di Mario</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Falk</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Folliguet</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Garg</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Huber</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>James</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Knuuti</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lopez-Sendon</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Marco</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Menicanti</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Ostojic</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Piepoli</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Pirlet</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Pomar</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Reifart</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Ribichini</surname>
                      <given-names>FL</given-names>
                    </name>
                    <name>
                      <surname>Schalij</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Sergeant</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Silber</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Sousa Uva</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Taggart</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Guidelines on myocardial revascularization.</article-title>
                  <source>Eur Heart J</source>
                  <year>2010</year>
                  <volume>31</volume>
                  <fpage>2501</fpage>
                  <lpage>2555</lpage>
                  <pub-id pub-id-type="pmid">20802248</pub-id>
                </element-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Iqbal</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Taggart</surname>
                      <given-names>DP.</given-names>
                    </name>
                  </person-group>
                  <article-title>Optimal revascularization for complex coronary artery
disease.</article-title>
                  <source>Nat Rev Cardiol</source>
                  <year>2013</year>
                  <volume>10</volume>
                  <fpage>635</fpage>
                  <lpage>647</lpage>
                  <comment>doi: 10.1038/nrcardio.2013.138</comment>
                  <pub-id pub-id-type="pmid">24042217</pub-id>
                </element-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kastrati</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mehilli</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Pache</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kaiser</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Valgimigli</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kelbaek</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Menichelli</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sabaté</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Suttorp</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Baumgart</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Seyfarth</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Pfisterer</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Schömig</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Analysis of 14 trials comparing sirolimus-eluting stents with
bare-metal stents.</article-title>
                  <source>N Engl J Med</source>
                  <year>2007</year>
                  <volume>356</volume>
                  <fpage>1030</fpage>
                  <lpage>1039</lpage>
                  <comment>doi: 10.1056/NEJMoa067484</comment>
                  <pub-id pub-id-type="pmid">17296823</pub-id>
                </element-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Virmani</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Guagliumi</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Farb</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Musumeci</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Grieco</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Motta</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Mihalcsik</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Tespili</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Valsecchi</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Kolodgie</surname>
                      <given-names>FD.</given-names>
                    </name>
                  </person-group>
                  <article-title>Localized hypersensitivity and late coronary thrombosis secondary
to a sirolimus-eluting stent: should we be cautious?</article-title>
                  <source>Circulation</source>
                  <year>2004</year>
                  <volume>109</volume>
                  <fpage>701</fpage>
                  <lpage>705</lpage>
                  <comment>doi: 10.1161/01.CIR.0000116202.41966.D4</comment>
                  <pub-id pub-id-type="pmid">14744976</pub-id>
                </element-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Camenzind</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Steg</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Wijns</surname>
                      <given-names>W.</given-names>
                    </name>
                  </person-group>
                  <article-title>Stent thrombosis late after implantation of first-generation
drug-eluting stents: a cause for concern.</article-title>
                  <source>Circulation</source>
                  <year>2007</year>
                  <volume>115</volume>
                  <fpage>1440</fpage>
                  <lpage>1455, discussion 1455</lpage>
                  <comment>doi: 10.1161/CIRCULATIONAHA.106.666800</comment>
                  <pub-id pub-id-type="pmid">17344324</pub-id>
                </element-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Daemen</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Wenaweser</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Tsuchida</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Abrecht</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Vaina</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Morger</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kukreja</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Jüni</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Sianos</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Hellige</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>van Domburg</surname>
                      <given-names>RT</given-names>
                    </name>
                    <name>
                      <surname>Hess</surname>
                      <given-names>OM</given-names>
                    </name>
                    <name>
                      <surname>Boersma</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Meier</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Windecker</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW.</given-names>
                    </name>
                  </person-group>
                  <article-title>Early and late coronary stent thrombosis of sirolimus-eluting and
paclitaxel-eluting stents in routine clinical practice: data from a large
two-institutional cohort study.</article-title>
                  <source>Lancet</source>
                  <year>2007</year>
                  <volume>369</volume>
                  <fpage>667</fpage>
                  <lpage>678</lpage>
                  <comment>doi: 10.1016/S0140-6736(07)60314-6</comment>
                  <pub-id pub-id-type="pmid">17321312</pub-id>
                </element-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stone</surname>
                      <given-names>GW</given-names>
                    </name>
                    <name>
                      <surname>Moses</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Ellis</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Schofer</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Dawkins</surname>
                      <given-names>KD</given-names>
                    </name>
                    <name>
                      <surname>Morice</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Colombo</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Schampaert</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Grube</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kirtane</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Cutlip</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>Fahy</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Pocock</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Mehran</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Leon</surname>
                      <given-names>MB.</given-names>
                    </name>
                  </person-group>
                  <article-title>Safety and efficacy of sirolimus- and paclitaxel-eluting coronary
stents.</article-title>
                  <source>N Engl J Med</source>
                  <year>2007</year>
                  <volume>356</volume>
                  <fpage>998</fpage>
                  <lpage>1008</lpage>
                  <comment>doi: 10.1056/NEJMoa067193</comment>
                  <pub-id pub-id-type="pmid">17296824</pub-id>
                </element-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nordmann</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Briel</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bucher</surname>
                      <given-names>HC.</given-names>
                    </name>
                  </person-group>
                  <article-title>Mortality in randomized controlled trials comparing drug-eluting
vs. bare metal stents in coronary artery disease: a
meta-analysis.</article-title>
                  <source>Eur Heart J</source>
                  <year>2006</year>
                  <volume>27</volume>
                  <fpage>2784</fpage>
                  <lpage>2814</lpage>
                  <comment>doi: 10.1093/eurheartj/ehl282</comment>
                  <pub-id pub-id-type="pmid">17020889</pub-id>
                </element-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pfisterer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Brunner-La Rocca</surname>
                      <given-names>HP</given-names>
                    </name>
                    <name>
                      <surname>Buser</surname>
                      <given-names>PT</given-names>
                    </name>
                    <name>
                      <surname>Rickenbacher</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Hunziker</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Mueller</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Jeger</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bader</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Osswald</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kaiser</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <collab>BASKET-LATE Investigators</collab>
                  <article-title>Late clinical events after clopidogrel discontinuation may limit
the benefit of drug-eluting stents: an observational study of drug-eluting
versus bare-metal stents.</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2006</year>
                  <volume>48</volume>
                  <fpage>2584</fpage>
                  <lpage>2591</lpage>
                  <comment>doi: 10.1016/j.jacc.2006.10.026</comment>
                  <pub-id pub-id-type="pmid">17174201</pub-id>
                </element-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lee</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Youn</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Oh</surname>
                      <given-names>IY</given-names>
                    </name>
                    <name>
                      <surname>Yoon</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>Suh</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Cho</surname>
                      <given-names>YS</given-names>
                    </name>
                    <name>
                      <surname>Cho</surname>
                      <given-names>GY</given-names>
                    </name>
                    <name>
                      <surname>Chae</surname>
                      <given-names>IH</given-names>
                    </name>
                    <name>
                      <surname>Choi</surname>
                      <given-names>DJ.</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparison of 9-month angiographic outcomes of Resolute
zotarolimus-eluting and everolimus-eluting stents in a real world setting of
coronary intervention in Korea.</article-title>
                  <source>BMC Cardiovasc Disord</source>
                  <year>2013</year>
                  <volume>13</volume>
                  <fpage>65</fpage>
                  <comment>doi: 10.1186/1471-2261-13-65</comment>
                  <pub-id pub-id-type="pmid">24011332</pub-id>
                </element-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>von Birgelen</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Basalus</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Tandjung</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>van Houwelingen</surname>
                      <given-names>KG</given-names>
                    </name>
                    <name>
                      <surname>Stoel</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Louwerenburg</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Linssen</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Saïd</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Kleijne</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Sen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Löwik</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>van der Palen</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Verhorst</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>de Man</surname>
                      <given-names>FH.</given-names>
                    </name>
                  </person-group>
                  <article-title>A randomized controlled trial in second-generation
zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V
stents in real-world patients: the TWENTE trial.</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2012</year>
                  <volume>59</volume>
                  <fpage>1350</fpage>
                  <lpage>1361</lpage>
                  <comment>doi: 10.1016/j.jacc.2012.01.008</comment>
                  <pub-id pub-id-type="pmid">22341737</pub-id>
                </element-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tandjung</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Basalus</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Louwerenburg</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Stoel</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>van Houwelingen</surname>
                      <given-names>KG</given-names>
                    </name>
                    <name>
                      <surname>de Man</surname>
                      <given-names>FH</given-names>
                    </name>
                    <name>
                      <surname>Linssen</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Saïd</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Nienhuis</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Löwik</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Verhorst</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>van der Palen</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>von Birgelen</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical outcome following stringent discontinuation of dual
antiplatelet therapy after 12 months in real-world patients treated with
second-generation zotarolimus-eluting resolute and everolimus-eluting Xience
V stents: 2-year follow-up of the randomized TWENTE trial.</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2013</year>
                  <volume>61</volume>
                  <fpage>2406</fpage>
                  <lpage>2416</lpage>
                  <comment>doi: 10.1016/j.jacc.2013.04.005</comment>
                  <pub-id pub-id-type="pmid">23602769</pub-id>
                </element-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Park</surname>
                      <given-names>KW</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Kang</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Ahn</surname>
                      <given-names>HS</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>HM</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>HY</given-names>
                    </name>
                    <name>
                      <surname>Kang</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Koo</surname>
                      <given-names>BK</given-names>
                    </name>
                    <name>
                      <surname>Cho</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gwon</surname>
                      <given-names>HC</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>SY</given-names>
                    </name>
                    <name>
                      <surname>Chae</surname>
                      <given-names>IH</given-names>
                    </name>
                    <name>
                      <surname>Youn</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Chae</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Han</surname>
                      <given-names>KR</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>CW</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>HS.</given-names>
                    </name>
                  </person-group>
                  <article-title>Safety and efficacy of second-generation everolimus-eluting
Xience V stents versus zotarolimus-eluting resolute stents in real-world
practice: patient-related and stent-related outcomes from the multicenter
prospective EXCELLENT and RESOLUTE-Korea registries.</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2013</year>
                  <volume>61</volume>
                  <fpage>536</fpage>
                  <lpage>544</lpage>
                  <comment>doi: 10.1016/j.jacc.2012.11.015</comment>
                  <pub-id pub-id-type="pmid">23273394</pub-id>
                </element-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Tandjung</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Löwik</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Stoel</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>de Man</surname>
                      <given-names>FH</given-names>
                    </name>
                    <name>
                      <surname>Louwerenburg</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>van Houwelingen</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Linssen</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Doggen</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Basalus</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>von Birgelen</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Complex patients treated with zotarolimus-eluting resolute and
everolimus-eluting Xience V stents in the randomized TWENTE trial:
comparison of 2-year clinical outcome.</article-title>
                  <source>Catheter Cardiovasc Interv</source>
                  <year>2015</year>
                  <volume>85</volume>
                  <fpage>74</fpage>
                  <lpage>81</lpage>
                  <comment>doi: 10.1002/ccd.25464</comment>
                  <pub-id pub-id-type="pmid">24585502</pub-id>
                </element-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stefanini</surname>
                      <given-names>GG</given-names>
                    </name>
                    <name>
                      <surname>Serruys</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Silber</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Khattab</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>van Geuns</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Richardt</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Buszman</surname>
                      <given-names>PE</given-names>
                    </name>
                    <name>
                      <surname>Kelbæk</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>van Boven</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Hofma</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Linke</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Klauss</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Wijns</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Macaya</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Garot</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Di Mario</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Manoharan</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Kornowski</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Ischinger</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Bartorelli</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Gobbens</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Windecker</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>The impact of patient and lesion complexity on clinical and
angiographic outcomes after revascularization with zotarolimus- and
everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a
randomized comparison of a zotarolimus-eluting stent with an
everolimus-eluting stent for percutaneous coronary
intervention).</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2011</year>
                  <volume>57</volume>
                  <fpage>2221</fpage>
                  <lpage>2232</lpage>
                  <comment>doi: 10.1016/j.jacc.2011.01.036</comment>
                  <pub-id pub-id-type="pmid">21616282</pub-id>
                </element-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>XT</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Ni</surname>
                      <given-names>ZH</given-names>
                    </name>
                    <name>
                      <surname>Xia</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Chi</surname>
                      <given-names>YH</given-names>
                    </name>
                    <name>
                      <surname>He</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>WM</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>HS</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>LF</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>XC.</given-names>
                    </name>
                  </person-group>
                  <article-title>Two-year clinical outcomes of patients with overlapping
second-generation drug-eluting stents for treatment of long coronary artery
lesions: comparison of everolimus-eluting stents with resolute
zotarolimus-eluting stents.</article-title>
                  <source>Coron Artery Dis</source>
                  <year>2014</year>
                  <volume>25</volume>
                  <fpage>405</fpage>
                  <lpage>411</lpage>
                  <comment>doi: 10.1097/MCA.0000000000000098</comment>
                  <pub-id pub-id-type="pmid">24584031</pub-id>
                </element-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mehilli</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Richardt</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Valgimigli</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schulz</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Abdel-Wahab</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tiroch</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Pache</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hausleiter</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Ott</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Ibrahim</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Fusaro</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Seyfarth</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Laugwitz</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Massberg</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kastrati</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <collab>ISAR-LEFT-MAIN 2 Study Investigators</collab>
                  <article-title>Zotarolimus- versus everolimus-eluting stents for unprotected
left main coronary artery disease.</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2013</year>
                  <volume>62</volume>
                  <fpage>2075</fpage>
                  <lpage>2082</lpage>
                  <comment>doi: 10.1016/j.jacc.2013.07.044</comment>
                  <pub-id pub-id-type="pmid">23973699</pub-id>
                </element-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cho</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Jeong</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Ahn</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Hong</surname>
                      <given-names>YJ</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>YJ</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Cho</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Han</surname>
                      <given-names>KR</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>HS</given-names>
                    </name>
                  </person-group>
                  <collab>Korea Acute Myocardial Infarction Registry Investigators</collab>
                  <article-title>Clinical outcomes of everolimus- and zotarolimus-eluting stents
in patients with acute myocardial infarction for small coronary artery
disease.</article-title>
                  <source>J Cardiol</source>
                  <year>2014</year>
                  <volume>63</volume>
                  <fpage>409</fpage>
                  <lpage>417</lpage>
                  <comment>doi: 10.1016/j.jjcc.2013.10.016</comment>
                  <pub-id pub-id-type="pmid">24314902</pub-id>
                </element-citation>
              </ref>
              <ref id="R34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferrarello</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Costopoulos</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Latib</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Naganuma</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Sticchi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Figini</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Basavarajaiah</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Carlino</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Chieffo</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Montorfano</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kawaguchi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Naim</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Giannini</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Colombo</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of everolimus-eluting and resolute zotarolimus-eluting
stents in the treatment of coronary bifurcations.</article-title>
                  <source>J Invasive Cardiol</source>
                  <year>2013</year>
                  <volume>25</volume>
                  <fpage>436</fpage>
                  <lpage>440</lpage>
                  <pub-id pub-id-type="pmid">23995715</pub-id>
                </element-citation>
              </ref>
              <ref id="R35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Park</surname>
                      <given-names>KW</given-names>
                    </name>
                    <name>
                      <surname>Kang</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Kang</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Koo</surname>
                      <given-names>BK</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>BE</given-names>
                    </name>
                    <name>
                      <surname>Cha</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Rhew</surname>
                      <given-names>JY</given-names>
                    </name>
                    <name>
                      <surname>Jeon</surname>
                      <given-names>HK</given-names>
                    </name>
                    <name>
                      <surname>Shin</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Oh</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Jeong</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Hwang</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>Yoon</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>SY</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>TH</given-names>
                    </name>
                    <name>
                      <surname>Moon</surname>
                      <given-names>KW</given-names>
                    </name>
                    <name>
                      <surname>Kwon</surname>
                      <given-names>HM</given-names>
                    </name>
                    <name>
                      <surname>Hur</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Ryu</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>BR</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>YW</given-names>
                    </name>
                    <name>
                      <surname>Chae</surname>
                      <given-names>IH</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>HS</given-names>
                    </name>
                  </person-group>
                  <collab>HOST–ASSURE Investigators</collab>
                  <article-title>A randomized comparison of platinum chromium-based
everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting
stents in all-comers receiving percutaneous coronary intervention:
HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery
stenosis-safety &amp; effectiveness of drug-eluting stents &amp;
anti-platelet regimen), a randomized, controlled, noninferiority
trial.</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2014</year>
                  <volume>63</volume>
                  <issue>25 pt A</issue>
                  <fpage>2805</fpage>
                  <lpage>2816</lpage>
                  <comment>doi: 10.1016/j.jacc.2014.04.013</comment>
                  <pub-id pub-id-type="pmid">24814486</pub-id>
                </element-citation>
              </ref>
              <ref id="R36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>von Birgelen</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Sen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Danse</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Jessurun</surname>
                      <given-names>GA</given-names>
                    </name>
                    <name>
                      <surname>Hautvast</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>van Houwelingen</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Schramm</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Gin</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Louwerenburg</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>de Man</surname>
                      <given-names>FH</given-names>
                    </name>
                    <name>
                      <surname>Stoel</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Löwik</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Linssen</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Saïd</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Nienhuis</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Verhorst</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Basalus</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Doggen</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Tandjung</surname>
                      <given-names>K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Third-generation zotarolimus-eluting and everolimus-eluting
stents in all-comer patients requiring a percutaneous coronary intervention
(DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority
trial.</article-title>
                  <source>Lancet</source>
                  <year>2014</year>
                  <volume>383</volume>
                  <fpage>413</fpage>
                  <lpage>423</lpage>
                  <comment>doi: 10.1016/S0140-6736(13)62037-1</comment>
                  <pub-id pub-id-type="pmid">24183564</pub-id>
                </element-citation>
              </ref>
              <ref id="R37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stone</surname>
                      <given-names>GW</given-names>
                    </name>
                    <name>
                      <surname>Teirstein</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Meredith</surname>
                      <given-names>IT</given-names>
                    </name>
                    <name>
                      <surname>Farah</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Dubois</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Feldman</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Dens</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hagiwara</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Allocco</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Dawkins</surname>
                      <given-names>KD</given-names>
                    </name>
                  </person-group>
                  <collab>PLATINUM Trial Investigators</collab>
                  <article-title>A prospective, randomized evaluation of a novel
everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized,
Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System
[PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery
Lesions) trial.</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2011</year>
                  <volume>57</volume>
                  <fpage>1700</fpage>
                  <lpage>1708</lpage>
                  <comment>doi: 10.1016/j.jacc.2011.02.016</comment>
                  <pub-id pub-id-type="pmid">21470815</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
